what is microdosing of glp-1 GLP-1s: Does It Work? Risks and Benefits Microdosing GLP-1: Should You Try

Description

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

Food preferences are shifting

Combining creatine with tirzepatide-based weight loss therapy requires careful consideration of kidney function and hydration status

Discover expert guidance on using these medications together, potential interactions, and practical tips for UK patients managing both acid reflux and weight loss treatment.

University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs, like Ozempic and Zepbound, on cancer risk.